Value through Innovation12 February 2016

Boehringer Ingelheim Press Releases

See the latest Boehringer Ingelheim news releases. To quickly find all news releases on a specific topic, please use the fulltext search.

Press Release Archive


Boehringer Ingelheim submits applications for approval of idarucizumab*, specific reversal agent to dabigatran etexilate (Pradaxa®), to EMA, FDA and Health Canada

- For Non-US/Non-UK Media

Innovative protection against Bovine Viral Diarrhea: Boehringer Ingelheim launches Bovela® in Europe


Boehringer Ingelheim Animal Health continues support of independent PCV2 research


New large-scale study to investigate effect of tiotropium + olodaterol Respimat® on exacerbations in COPD

- For media outside the US, the UK and Canada

OFEV® (nintedanib*) approved in the EU for the treatment of IPF

- For media outside UK, US and Canada

Boehringer Ingelheim and Sanofi enter into a strategic contract manufacturing alliance to produce biopharmaceuticals


35 partners from industry and academia to join European research initiative for the prevention of Alzheimer’s dementia


Boehringer Ingelheim and Vanderbilt University join forces to develop new Ras inhibitors for cancer treatment


Boehringer Ingelheim and Yale University collaborate to investigate novel immunotherapy targets across several therapeutic areas


The Lancet Oncology publishes Phase III data showing Giotrif® (afatinib*) significantly extended overall survival of lung cancer patients with the most common EGFR mutation over chemotherapy

- For media outside UK, US and Canada only

New vaccine against Bovine Viral Diarrhea: Boehringer Ingelheim receives European marketing authorization for Bovela®


First trial of a novel oral anticoagulant starts in prevention of recurrent stroke due to a blood clot of undetermined source

- For Non-US/Non-UK/Non-Canadian Media

Boehringer Ingelheim LUX-Breast 1 and LUX-Breast 3 data at San Antonio Breast Cancer Symposium (SABCS)

- For Media Outside the UK, US and Canada Only

New data show specific antidote idarucizumab* reverses dabigatran-induced anticoagulation also in elderly and renally impaired volunteers

- For Non-US/Non-UK/Non-Canadian Media

Investing in the development of innovative active ingredients: Boehringer Ingelheim opens a new technology centre in Biberach


Vargatef® (nintedanib*) approved in the EU for lung cancer patients with advanced adenocarcinoma after first-line chemotherapy

- For media outside UK, US and Canada only

Nintedanib* receives positive CHMP opinion in European Union for the treatment of IPF

- For media outside UK, US and Canada

Two new, large scale real-world analyses show fewer major bleeds and strokes with Pradaxa® than with warfarin

- For Non-US/Non-UK/Non-Canadian Media